February 28, 2015 7:58 PM ET


Company Overview of Aerpio Therapeutics, Inc.

Company Overview

Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of diabetic eye disease and inflammatory bowel disease. It offers tie-2 activators and HIF-1 stabilizers. The company was incorporated in 2011 and is based in Cincinnati, Ohio.

9987 Carver Road

Suite 420

Cincinnati, OH 45242

United States

Founded in 2011





Key Executives for Aerpio Therapeutics, Inc.

Chief Executive Officer and Director
Chief Financial Officer and Vice President
Age: 55
Chief Medical Officer
Age: 59
Chief Scientific Officer
Compensation as of Fiscal Year 2014.

Aerpio Therapeutics, Inc. Key Developments

Aerpio Therapeutics Announces Publication of Preclinical Data on AKB-9778 for Common Eye Diseases

Aerpio Therapeutics, Inc. announced the publication of preclinical data demonstrating that lead candidate, AKB-9778, reduces abnormal blood vessel growth and leakage in mouse models of ophthalmic diseases, such as diabetic macular edema (DME) and age-related macular degeneration. These data were published in collaboration with researchers at Johns Hopkins School of Medicine, Max Planck Institute, and Duke University in the September 2, 2014, issue of The Journal of Clinical Investigation. AKB-9778 is a small molecule activator of Tie2 currently in a Phase 2 clinical study for the treatment of DME. The results of the JCI study clearly demonstrate the potential benefit of restoring Tie2 activation in mouse models of major vision-robbing eye diseases. Importantly, the results support the benefit of AKB-9778 as either a monotherapy or as an adjunct to anti-VEGF agents.

Aerpio Therapeutics, Inc. Announces Full Results from Phase 1b/2a Study of AKB-9778 for the Treatment of Diabetic Macular Edema

Aerpio Therapeutics, Inc. announced the presentation of the full results of its Phase 1b/2a study of Tie2 activator, AKB-9778, for the treatment of diabetic macular edema (DME) at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) in Orlando, FL. In the study, one month of daily AKB-9778 treatment was well-tolerated, produced clinically meaningful reduction in retinal thickness, with concomitant improvement in visual acuity, in some of the patients. Tie2 plays a central role in maintaining vascular integrity, which prevents vascular leak seen in conditions such as DME. AKB-9778 activates Tie2 by inhibiting the natural brake of Tie2, human protein tyrosine phosphatase (HPTP). This is the first study to show that activation of Tie2 can have a beneficial effect in patients with DME.

Aerpio Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 09:20 AM

Aerpio Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 09:20 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Joseph H. Gardner, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
La Haye Laboratories, Inc. United States
Pharbco Marketing Group, Inc. United States
United Hospital Supply Corporation United States
JDS Therapeutics, LLC United States
Biologics Process Development, Inc. United States

Recent Private Companies Transactions

Private Placement
April 22, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aerpio Therapeutics, Inc., please visit www.aerpio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.